ALZ Stock Overview
A biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Alzinova AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.48 |
| 52 Week High | SEK 4.62 |
| 52 Week Low | SEK 0.95 |
| Beta | 1.25 |
| 1 Month Change | -3.87% |
| 3 Month Change | -8.90% |
| 1 Year Change | 11.00% |
| 3 Year Change | -48.44% |
| 5 Year Change | -73.23% |
| Change since IPO | -73.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALZ | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.8% | 1.1% | -3.3% |
| 1Y | 11.0% | 14.6% | 4.8% |
Return vs Industry: ALZ underperformed the Swedish Biotechs industry which returned 12.8% over the past year.
Return vs Market: ALZ exceeded the Swedish Market which returned 6.5% over the past year.
Price Volatility
| ALZ volatility | |
|---|---|
| ALZ Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ALZ has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ALZ's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5 | Tord Labuda | www.alzinova.com |
Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer’s disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study.
Alzinova AB (publ) Fundamentals Summary
| ALZ fundamental statistics | |
|---|---|
| Market cap | SEK 310.30m |
| Earnings (TTM) | -SEK 18.72m |
| Revenue (TTM) | SEK 17.39m |
17.8x
P/S Ratio-16.6x
P/E RatioIs ALZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALZ income statement (TTM) | |
|---|---|
| Revenue | SEK 17.39m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 17.39m |
| Other Expenses | SEK 36.11m |
| Earnings | -SEK 18.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 100.00% |
| Net Profit Margin | -107.64% |
| Debt/Equity Ratio | 0.6% |
How did ALZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 11:21 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alzinova AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ludvig Svensson | Penser Access |
| Maria Karlsson Osipova | Penser Access |
| Kevin Sule | Redeye |